Drug intelligence / Profile preview

ABBV-011 + budigalimab

Development stage: Unknown
Lead developer: AbbVie
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ABBV-011 + budigalimab is a **combination therapy** under investigation for the treatment of relapsed or refractory small cell lung cancer (SCLC). ABBV-011 is a **SEZ6-targeted antibody-drug conjugate (ADC)** consisting of a monoclonal antibody targeting the seizure-related homolog 6 protein (SEZ6) linked to a calicheamicin cytotoxic payload, designed to deliver targeted cytotoxicity to SEZ6-positive cancer cells. Budigalimab (ABBV-181) is a **monoclonal antibody that inhibits programmed cell death protein 1 (PD-1)**, serving as an immune checkpoint inhibitor to enhance antitumor immune responses. The combination aims to leverage direct tumor cell killing via the ADC and immune activation through checkpoint inhibition. Currently, this combination is being evaluated in phase 1 clinical trials primarily in SCLC[1][3][5][6].

Other names: ABBV-011 + ABBV-181

Targets

SEZ6PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ABBV-011 + budigalimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-011 + budigalimab.

Explore the full profile